Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics adds Charles Fuchs to its board of directors

Neutral Impact 2 of 5 leadership Written later

CytomX Therapeutics appointed Dr. Charles Fuchs to its Board of Directors effective July 24, 2026, as a Class II director with a term running to the 2029 annual meeting. The filing says he received an option to buy 118,000 shares of common stock, vesting monthly over three years, which ties part of his pay to the stock price.

Key points

  • Charles Fuchs, M.D., M.P.H., joined the board effective July 24, 2026, as a Class II director.
  • His initial term expires at the 2029 annual meeting of stockholders.
  • He received an option to purchase 118,000 shares at the July 24, 2026 closing price, vesting in 1/36th installments monthly.

The filing

CompanyCytomX Therapeutics, Inc. (CTMX)
Form8-K, current report
Filed with the SECJul 27, 2026, 8:05 AM ET
Accession number0001193125-26-316929

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.